Resultats de la cerca - Edward R. Scheffer Cliff

  • Mostrar 1 - 10 resultats de 10
Refinar resultats
  1. 1
    Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma

    Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma per Edward R. Scheffer Cliff, Gemma Reynolds, Rakesh Popat, Benjamin W. Teh, Aaron S. Kesselheim, Ghulam Rehman Mohyuddin

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  2. 2
    High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

    High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions per Edward R. Scheffer Cliff, Amar H. Kelkar, David A. Russler‐Germain, Frazer A. Tessema, Adam Raymakers, William B. Feldman, Aaron S. Kesselheim

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis

    Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis per Gemma Reynolds, Marsali Maclean, Edward R. Scheffer Cliff, Benjamin W. Teh, Karin Thursky, Monica A. Slavin, Mary Ann Anderson, Eliza A. Hawkes

    Publicat 2024
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

    Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis per Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, Rakesh Popat, Shonali Midha, Melissa Ng, Simon J. Harrison, Aaron S. Kesselheim, Benjamin W. Teh

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    The lucent yet opaque challenge of regulating artificial intelligence in radiology

    The lucent yet opaque challenge of regulating artificial intelligence in radiology per James Hillis, Jacob J. Visser, Edward R. Scheffer Cliff, Kelly van der Geest – Aspers, Bernardo C. Bizzo, Keith J. Dreyer, Jeremias Adams‐Prassl, Katherine P. Andriole

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

    Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma per Tobias Tix, Mohammad Alhomoud, Roni Shouval, Gloria Iacoboni, Edward R. Scheffer Cliff, Doris K. Hansen, Saad Z. Usmani, Gilles Salles, Miguel‐Angel Perales, David M. Cordas dos Santos, Kai Rejeski

    Publicat 2025
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Dietary interventions in cancer: a systematic review of all randomized controlled trials

    Dietary interventions in cancer: a systematic review of all randomized controlled trials per Nosakhare Paul Ilerhunmwuwa, Abul Hasan Shadali Abdul Khader, Calvin Smith, Edward R. Scheffer Cliff, Christopher M. Booth, Evevanne Hottel, Muhammad Aziz, Wade Lee‐Smith, Aaron M. Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

    A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy per David M. Cordas dos Santos, Tobias Tix, Roni Shouval, Anat Gafter‐Gvili, Jean-Baptiste Alberge, Edward R. Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt‐Baildon, Irene M. Ghobrial, Kai Rejeski, Miguel‐Angel Perales, Kai Rejeski

    Publicat 2024
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition per Thomas E. Lew, Victor S. Lin, Edward R. Scheffer Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David Westerman, Bryone J. Kuss, Constantine S. Tam, David C.S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

    Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma per Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Anikó Szabó, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan

    Publicat 2024
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:

Eines de cerca: